Post-earnings recap
Reported
Mon, Jan 28, 2013
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
Biogen's earnings report showed a slight miss on EPS, which may raise concerns among investors about profitability. However, the stock rose by 2.59%, likely driven by management's positive outlook on ongoing research and development efforts. The lack of revenue data and guidance leaves some uncertainty about future performance.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.40 | N/A | -4.11% |
Management expressed a focus on long-term growth through R&D. They acknowledged the EPS miss but remained positive about future developments.
Management highlighted ongoing research efforts and commitment to innovation.
They noted the importance of maintaining a strong pipeline despite the EPS miss.
Est. EPS
—
Est. Rev
—
Impl. Move
—